Literature DB >> 15353396

Donepezil in the treatment of dementia with lewy bodies.

David Q Beversdorf, Jennifer L Warner, Rebecca A Davis, Umesh K Sharma, Haikady N Nagaraja, Douglas W Scharre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353396     DOI: 10.1176/appi.ajgp.12.5.542

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


× No keyword cloud information.
  7 in total

1.  Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  D Aarsland; C Ballard; A Rongve; M Broadstock; P Svenningsson
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 2.  Cognitive impairment and dementia in basal ganglia disorders.

Authors:  Julie C Stout; Shannon A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 3.  Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.

Authors:  Brit Mollenhauer; Hans Förstl; Günther Deuschl; Alexander Storch; Wolfgang Oertel; Claudia Trenkwalder
Journal:  Dtsch Arztebl Int       Date:  2010-10-01       Impact factor: 5.594

Review 4.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 5.  [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors].

Authors:  I Liepelt; W Maetzler; H-P Blaicher; T Gasser; D Berg
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 6.  Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Authors:  Michal Rolinski; Chris Fox; Ian Maidment; Rupert McShane
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

Review 7.  Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.

Authors:  Shinji Matsunaga; Taro Kishi; Ichiro Yasue; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-28       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.